Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: Placenta. 2008 Nov 17;30(1):25–34. doi: 10.1016/j.placenta.2008.10.006

Fig. 5.

Fig. 5

Soluble Flt-1 variants bind exogenous VEGF protein. In order to show that these variants are capable of binding VEGF, their functional target, VEGF (1 μg) was added to the heparin-agarose enriched sFlt-1 fraction, immunoprecipitated the sFlt-1/VEGF complex with anti-VEGF antibody (Pharmingen, San Diego, CA) and then probed for sFlt-1 with Sigma antibody (A). Lanes 1 and 3 show the input heparin-agarose sFlt-1 from plasma and conditioned medium, respectively. Lanes 2 and 4 show the sFlt-1 receptors that were immunoprecipitated using anti VEGF antibody. Immunoprecipitates from the same experiment were analyzed by Western blot using antibody from Santa Cruz (B) to demonstrate that the 150 and 185 kDa variants were also capable of binding VEGF protein.